Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADE: TAK-935 in Dup15q syndrome or CDKL5 deficiency disorder
CTR20191891Phase 2Suspended
- Sponsor
- Takeda
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soticlestat in dup15q syndrome, CDKL5 deficiency disorder (CDD), sponsored by Takeda. Started Jul 2021; status: suspended.
02
Drugs
soticlestat
03
Conditions
dup15q syndromeCDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on CTR20191891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191891.